Novartis erzielte im ersten Quartal mit prioritären Marken und Neueinführungen ein starkes Wachstum; Prognose für das Geschäftsjahr 2026 bekräftigt
arcticnovartis
Tue, 04/28/2026 – 07:03
Read more about Novartis erzielte im ersten Quartal mit prio…
Novartis delivered strong growth in priority brands and launches in Q1; FY 2026 guidance reaffirmed
arcticnovartis
Tue, 04/28/2026 – 07:03
Read more about Novartis delivered strong growth in priority brands and launches in Q1; FY 2026 guidance rea…
Novartis Rhapsido® receives European Commission approval as first oral targeted treatment for chronic spontaneous urticaria
arcticnovartis
Mon, 04/27/2026 – 07:19
Read more about Novartis Rhapsido® receives European …
Novartis receives positive CHMP opinion for Itvisma® for spinal muscular atrophy (SMA)
arcticnovartis
Fri, 04/24/2026 – 12:34
Read more about Novartis receives positive CHMP opinion for Itvisma® for spinal muscular atrophy (SMA)
If…
Novartis receives positive CHMP opinion for Itvisma® for spinal muscular atrophy (SMA)
arcticnovartis
Fri, 04/24/2026 – 12:34
Read more about Novartis receives positive CHMP opinion for Itvisma® for spinal muscular atrophy (SMA)
If…
Novartis malaria treatment Coartem® Baby receives WHO prequalification, paving way for greater access for newborns and young infants
arcticnovartis
Fri, 04/24/2026 – 07:19
Read more about Novartis malaria treatment Coartem® Baby receives WHO prequ…
Novartis malaria treatment Coartem® Baby receives WHO prequalification, paving way for greater access for newborns and young infants
arcticnovartis
Fri, 04/24/2026 – 07:17
Read more about Novartis malaria treatment Coartem® Baby receives WHO prequ…
Novartis announces expansion of community health programs to close gaps in heart disease and cancer care, targeting more than 30 countries by 2030
arcticnovartis
Thu, 04/09/2026 – 07:19
Read more about Novartis announces expansion of community hea…
Novartis IgAN data in New England Journal of Medicine show Fabhalta® slowed kidney function decline by 49.3%
arcticnovartis
Sun, 03/29/2026 – 07:19
Read more about Novartis IgAN data in New England Journal of Medicine show Fabhalta® slowed kidney …
Novartis agrees to acquire Excellergy, Inc., building on allergy leadership with next-generation anti-IgE innovation
arcticnovartis
Fri, 03/27/2026 – 07:02
Read more about Novartis agrees to acquire Excellergy, Inc., building on allergy leadership…